Pulse Biosciences (NASDAQ:PLSE) Upgraded to "Sell" at StockNews.com

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) was upgraded by equities research analysts at StockNews.com to a "sell" rating in a report released on Thursday.

Pulse Biosciences Price Performance

NASDAQ:PLSE traded up $0.38 during mid-day trading on Thursday, reaching $17.79. The company's stock had a trading volume of 128,357 shares, compared to its average volume of 199,506. The firm's fifty day moving average price is $18.02 and its two-hundred day moving average price is $16.90. Pulse Biosciences has a 12-month low of $6.59 and a 12-month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the company earned ($0.19) earnings per share.

Insider Buying and Selling at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan purchased 56,054 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was acquired at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the purchase, the director now directly owns 42,228,057 shares of the company's stock, valued at $732,656,788.95. This trade represents a 0.13 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the transaction, the chief executive officer now owns 63,172 shares of the company's stock, valued at approximately $1,100,456.24. This represents a 44.18 % decrease in their position. The disclosure for this sale can be found here. Insiders own 71.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Quest Partners LLC bought a new stake in shares of Pulse Biosciences in the 2nd quarter valued at approximately $91,000. Rhumbline Advisers lifted its position in Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock worth $288,000 after buying an additional 1,608 shares during the last quarter. Franklin Resources Inc. purchased a new position in Pulse Biosciences during the third quarter worth $378,000. Creative Planning increased its position in Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after acquiring an additional 11,667 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after acquiring an additional 23,738 shares during the period. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.